BDX:NYE-Becton Dickinson and Company (USD)

COMMON STOCK | Medical Instruments & Supplies | NYE

Last Closing Price

USD 252.89

Change

+4.45 (+1.79)%

Market Cap

USD 70.82B

Volume

1.13M

Avg Analyst Target

USD 287.00 (+13.49%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Becton Dickinson and Company (BDX) Stock Analysis:
Based on the Becton Dickinson and Company stock forecasts from 6 analysts, the average analyst target price for Becton Dickinson and Company is USD 287.00 over the next 12 months. Becton Dickinson and Company’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Becton Dickinson and Company is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Becton Dickinson and Company’s stock price was USD 252.89. Becton Dickinson and Company’s stock price has changed by +0.27% over the past week, -6.92% over the past month and +4.34% over the last year.

About

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public world ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BAX Baxter International Inc

+0.66 (+0.90%)

USD36.77B 34.96 20.62
ALC Alcon AG

+0.32 (+0.45%)

USD34.89B 93.38 20.45
RMD ResMed Inc

+0.05 (+0.03%)

USD29.29B 37.15 24.35
WST West Pharmaceutical Services I..

-1.60 (-0.52%)

USD22.59B 34.01 24.92
VAR Varian Medical Systems, Inc

N/A

USD16.26B 58.40 32.91
COO The Cooper Companies Inc

+0.12 (+0.04%)

USD16.16B 17.41 23.27
TFX Teleflex Incorporated

+2.88 (+1.03%)

USD13.06B 27.08 16.47
HRC Hill-Rom Holdings Inc

N/A

USD10.30B 41.92 21.82
ATR AptarGroup Inc

+0.82 (+0.76%)

USD7.05B 32.59 14.22
NVST Envista Holdings Corporation

+0.03 (+0.07%)

USD6.79B 21.81 15.81

ETFs Containing BDX

Symbol Name Weight Mer Price(Change) Market Cap
IBDK iShares iBonds Dec 2019 T.. 0.00 % 0.10 %

N/A

USD0.63B
IHI iShares U.S. Medical Devi.. 0.00 % 0.41 %

-0.05 (-0.09%)

USD7.41B
LS:CA Middlefield Healthcare & .. 0.00 % 0.85 %

N/A

USD0.08B
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.65 %

+47.50 (+0.21%)

USD0.07B
TACE Trend Aggregation Conserv.. 0.00 % 1.87 %

N/A

N/A
TEQI T. Rowe Price Equity Inco.. 0.00 % 0.54 %

+0.13 (+0.37%)

N/A
OWLU:XETRA Ossiam World ESG Machine .. 0.00 % 0.65 %

-0.34 (-0.31%)

USD0.04B
ASPY ASYMshares® ASYMmetric 5.. 0.00 % 0.95 %

+0.03 (+0.13%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.56% 95% A 82% B-
Dividend Return 0.35% 55% F 21% F
Total Return 0.91% 95% A 82% B-
Trailing 12 Months  
Capital Gain 4.89% 95% A 82% B-
Dividend Return 1.41% 90% A- 29% F
Total Return 6.30% 95% A 81% B-
Trailing 5 Years  
Capital Gain 39.35% 33% F 67% D+
Dividend Return 8.68% 89% B+ 30% F
Total Return 48.03% 42% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 5.05% 16% F 50% F
Dividend Return 1.33% 73% C 31% F
Total Return 6.38% 16% F 43% F
Risk Return Profile  
Volatility (Standard Deviation) 10.15% 95% A 81% B-
Risk Adjusted Return 62.86% 47% F 75% C
Market Capitalization 70.82B 100% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.15 25% F 14% F
Price/Book Ratio 2.89 61% D- 28% F
Price / Cash Flow Ratio 15.24 61% D- 26% F
EV/EBITDA 18.25 53% F 22% F
Management Effectiveness  
Return on Equity 7.23% 56% F 39% F
Return on Invested Capital 6.38% 53% F 54% F
Return on Assets 3.46% 47% F 59% F
Debt to Equity Ratio 72.26% 27% F 48% F
Technical Ratios  
Dividend Yield 1.40% 73% C 10% F
Short Ratio 3.34 72% C- 33% F
Short Percent 1.34% 89% B+ 72% C-
Beta 0.65 74% C 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.